Liquid Biopsy Market: Is 2026 the Year "Exosome...

hat ein neuen Blog hinzugefügt Health

2026-03-05 11:19:36 -

Liquid Biopsy Market: Is 2026 the Year "Exosome Profiling" Overtakes DNA Sequencing in Diagnostic Accuracy

While DNA has long been the star of the Liquid Biopsy Market, 2026 is officially the year of the "Exosome." These tiny extracellular vesicles are becoming the most valuable biomarker in 2026 because they carry a rich "cargo" of proteins and RNA that reflects the real-time metabolic state of a tumor. The 2026 market for "Exosome-Based Assays" is growing at a fastest-in-class 13.7% CAGR, as...

0 Kommentare 0 Geteilt 89 Ansichten 0 Bewertungen